When is belzutifan the right option for von Hippel-Lindau disease-associated hemangioblastomas?-a critical review of LITESPARK-004 results
- PMID: 40530135
- PMCID: PMC12170006
- DOI: 10.21037/tcr-2024-2478
When is belzutifan the right option for von Hippel-Lindau disease-associated hemangioblastomas?-a critical review of LITESPARK-004 results
Keywords: Von Hippel-Linday disease (VHL disease); belzutifan; hemangioblastoma; hypoxia inducible factor-2α (HIF-2α).
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2478/coif). U.S. received one-time consulting fees from Alexion Pharmaceuticals and Servier Pharmaceuticals; and one-time speaker fee from Merck & Co., Inc. The other author has no conflicts of interest to declare.
Comment on
-
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2024 Oct;25(10):1325-1336. doi: 10.1016/S1470-2045(24)00389-9. Epub 2024 Sep 13. Lancet Oncol. 2024. PMID: 39284337 Free PMC article. Clinical Trial.
References
-
- Zhuang Z, Gnarra JR, Dudley CF, et al. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Mod Pathol 1996;9:838-42. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources